Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 82% primary Improvement Relative Risk Mortality (b) 94% Mortality (c) 45% Mortality (d) 94% Mortality (e) 82% c19ivm.org Niaee et al. Ivermectin for COVID-19 RCT LATE TREATMENT Is late treatment with ivermectin beneficial for COVID-19? Double-blind RCT 180 patients in Iran Lower mortality with ivermectin (p=0.0011) Niaee et al., Asian Pacific J. Tropical Medicine, doi:10.4103/1995-7645.318304 Favors ivermectin Favors control
Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial
Niaee et al., Asian Pacific Journal of Tropical Medicine, doi:10.4103/1995-7645.318304 (date from earlier preprint)
Niaee et al., Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center.., Asian Pacific Journal of Tropical Medicine, doi:10.4103/1995-7645.318304 (date from earlier preprint)
Nov 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
82% lower mortality with ivermectin. RCT with 180 hospitalized patients showing reduced mortality and hospital stay with ivermectin, with a wide margin of safety. All patients received SOC including low dose HCQ. Analysis suggests randomization failure [twitter.com]. This study was reported as pending retraction, however the journal has indicated that this is incorrect and no retraction is pending. This study is excluded in the after exclusion results of meta analysis: analysis suggests randomization failure.
risk of death, 81.8% lower, RR 0.18, p = 0.001, treatment 4 of 120 (3.3%), control 11 of 60 (18.3%), NNT 6.7, All IVM vs. all control, primary outcome.
risk of death, 94.3% lower, RR 0.06, p = 0.01, treatment 0 of 30 (0.0%), control 11 of 60 (18.3%), NNT 5.5, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), IVM single dose 200mcg/kg vs. all control.
risk of death, 45.5% lower, RR 0.55, p = 0.37, treatment 3 of 30 (10.0%), control 11 of 60 (18.3%), NNT 12, IVM three dose 200mcg/kg vs. all control.
risk of death, 94.3% lower, RR 0.06, p = 0.01, treatment 0 of 30 (0.0%), control 11 of 60 (18.3%), NNT 5.5, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), IVM single dose 400mcg/kg vs. all control.
risk of death, 81.8% lower, RR 0.18, p = 0.06, treatment 1 of 30 (3.3%), control 11 of 60 (18.3%), NNT 6.7, IVM three dose 400/200/200mcg/kg vs. all control.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Niaee et al., 24 Nov 2020, Double Blind Randomized Controlled Trial, Iran, peer-reviewed, mean age 56.0, 14 authors, dosage 400μg/kg single dose, dose varies in different groups.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Abstract: [ 266 Asian Pacific Journal of Tropical Medicine 2021; 14(6): 266-273 apjtm.org Original Article Asian Pacific Journal of Tropical Medicine doi: 10.4103/1995-7645.318304 Impact Factor: 1.94 Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial Morteza Shakhsi Niaee1, Peyman Namdar2, Abbas Allami3, Leila Zolghadr4, Amir Javadi5, Amin Karampour3, Mehran Varnaseri6, Behzad Bijani7, Fatemeh Cheraghi1, Yazdan Naderi8, Fatemeh Amini9, Masoumeh Karamyan6,  Mohammad Jafar YadYad6, Ramin Jamshidian6, Nematollah Gheibi8 Sciences and Technology Park, Qazvin, Iran 1 Department of Surgery, Qazvin University of Medical Sciences, Qazvin, Iran 2 Department of Infectious Diseases, Clinical Research Development Unit, BouAliSina Hospital, Qazvin University of Medical Sciences, Qazvin, Iran 3 Department of Chemistry, Imam Khomeini International University Qazvin, Iran 4 Department of Social Sciences School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran 5 Infectious and Tropical Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran 6 Department of Infectious Diseases, Qazvin University of Medical Sciences, Qazvin, Iran 7 Cellular and Molecular Research Center, Research Institute for Prevention of Non-Communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran 8 Department of Persian Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran 9 ABSTRACT Objective: To evaluate different doses of ivermectin in adult patients with mild COVID-19 and to evaluate the effect of ivermectin on mortality and clinical consequences. Methods: A randomized, double-blind, placebo-controlled, multicenter clinical trial was performed at five hospitals. A total of 180 mild hospitalized patients with COVID-19 confirmed by PCR or chest image tests were enrolled and allocated to six arms including hydroxychloroquine 200 mg twice per day, placebo plus hydroxychloroquine 200 mg twice per day, single dose ivermectin (200 µg/kg), three low interval doses of ivermectin (200, 200, 200 µg/kg), single dose ivermectin (400 µg/kg), and three high interval doses of ivermectin (400, 200, 200 µg/kg). The primary endpoint of this trial was all-cause of mortality or clinical recovery. The radiographic findings, hospitalization and low O2 saturation duration, and hematological variables of blood samples were analyzed. Results: A total of 16.7% (5/30) and 20.0% (6/30) patients died in arms treated with hydroxychloroquine 200 mg twice per day and placebo plus hydroxychloroquine 200 mg twice per day, respectively, and a reduction in mortality rate in patients receiving ivermectin treatment to 0%, 10%, 0% and 3.3% for arms 1-4 were observed. Risk of mortality was also decreased about 15% in the ivermectin treated arms. Conclusions: Ivermectin as an adjunct reduces the rate of mortality, time of low O2 saturation, and duration of hospitalization in adult COVID-19 patients. The improvement of other clinical parameters shows that ivermectin, with a wide margin of safety, had a high therapeutic effect on COVID-19. KEYWORDS: SARS-COV-2; Ivermectin; Randomized controlled trial; Dose-respond relationship
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit